B. Griffith, H. Gamage, U. Kubhar, R. Khosravi-Far
InnoTech Precision Medicine Inc,
United States
Keywords: precision diagnosis, multiomics, genomics, transcriptomics, proteomics, epigenomics
Summary:
InnoTech Precision Medicine is pioneering an AI-integrated multiomics diagnostic platform designed for rapid, accurate, and non-invasive disease detection at the point of care. Our lab-on-a-chip technology enables simultaneous analysis of a combination of genomic, transcriptomic, proteomic, and epigenomic biomarkers, providing a comprehensive molecular profile in a single test. This technology is initially focused on non-invasive diagnosis of HPV-driven oropharyngeal cancers (OPSCC), but is designed as a scalable platform for broad applications in oncology, infectious diseases, and chronic conditions. Our proprietary cartridge system automates complex sample preparation, amplification, and detection processes, integrating multiple biomolecular assays into a single, cost-effective diagnostic tool. The system utilizes multiplexing to detect and quantify genes, transcripts, proteins, and epigenetic markers from saliva or blood samples. By incorporating nucleic acid amplification and biosensor technology, it ensures high-sensitivity detection without requiring large laboratory equipment. The platform is further enhanced by AI-driven analytics and decision support, where machine learning algorithms refine signal processing, biomarker pattern recognition, and disease risk stratification, significantly enhancing diagnostic accuracy while minimizing false positives and negatives. Additionally, the automated cloud-based data interpretation provides real-time insights to assist clinicians in making informed treatment decisions. Our multiomics approach offers superior disease detection capabilities to single-biomarker or multiplex of single-biomarker tests, improving sensitivity, specificity, and predictive power. Furthermore, the non-invasive, saliva-based testing eliminates the need for invasive biopsies, making early disease screening more accessible, affordable, and equitable, particularly for underserved and rural populations. This technology has the potential to bridge healthcare disparities by delivering high-quality diagnostics outside of traditional hospital settings. The beachhead market for our platform is HPV-driven cancers, but its versatility extends into broader applications, including early cancer detection (lung, colorectal, breast), infectious disease diagnostics (COVID-19, sepsis, antimicrobial resistance), and neurodegenerative and metabolic disease monitoring (Alzheimer’s, diabetes). We are actively collaborating Backed by NSF SBIR, NIH funding, and angel investors, InnoTech is positioned to redefine precision diagnostics, accelerate early disease detection, and improve patient outcomes worldwide. By combining advanced multi-omics biomarker detection and AI-powered analytics, our platform represents the future of precision medicine, enabling faster, more accurate, and equitable diagnostics for a wide range of diseases.